



MEDIGARD LIMITED

Office 14A, Tedder Terraces, 26-30 Tedder Avenue, Main Beach QLD 4217

Telephone +61 7 5528 0370; Fax +61 7 5528 0275

E-mail office@medigard.com.au www.medigard.com.au

ABN 49 090 003 044

30 August, 2010

Manager of Company Announcements
Australian Stock Exchange Limited
Level 6, 20 Bridge Street
SYDNEY NSW 2000

By e-lodgement

No of pages: 10 inclusive

Completion of Renounceable Rights Issue

Medigard is pleased to advise that its Renounceable Rights Issue announced on 27 July, 2010 has now closed. A total of \$990,298.86 has been raised at \$0.065 for the issue of 15,235,367 shares. In addition, \$68,224.91 has been raised by way of application for 1,049,614 additional shares also at \$0.065. The total raised including application for additional shares is \$1,058,523.77. The number of eligible shareholders subscribing to the offer was 251.

As disclosed in the Rights Issue Prospectus, as the issue has not been fully subscribed the funds raised will be directed towards the tooling and assembly equipment for Medigard's blood collection device, working capital and capital raising expenses.

Allotment will take place on Thursday 2 September, 2010 with despatch of holding statements to occur on the same day. Listing of the new shares has been sought for Friday 3 September, 2010.

The shortfall from the rights issue is approximately \$3.74 million and the Company will deal with the shortfall as disclosed in Section 1.6 of the Rights Issue Prospectus.

The directors wish to extend their appreciation to shareholders for their participation in the Renounceable Rights Issue and for their continued support.

Attached is relevant Appendix 3B seeking quotation of the additional securities.

Peter Emery
Chief Executive Officer

For further information contact:
Peter Emery, Telephone (07) 5528 0370

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

MEDIGARD LIMITED

ABN

49 090 003 044

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|--|---|
| 1 | +Class of +securities issued or to be issued | Fully paid ordinary shares
Options to acquire ordinary shares in the Company |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 16,284,981 shares
16,284,981 options |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Shares will be on identical terms as existing fully paid ordinary shares
Options will be issued on identical terms with an exercise price of 9.5 cents (\$0.095) and an expiry date of 30 June, 2011 |

<p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>Yes</p>							
<p>5 Issue price or consideration</p>	<p>6.5 cents per share. The options were issued as attaching to each share for no consideration</p>							
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>Issued by way of participation in the Company's Renounceable Rights Issue announced 27 July, 2010. Funds will be utilised for production tooling and assembly and for other working capital requirements.</p>							
<p>7 Dates of entering +securities into uncertificated holdings or despatch of certificates</p>	<p>Despatch date 2 September, 2010 Listing date 3 September, 2010</p>							
<p>8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)</p>	<table border="1"> <thead> <tr> <th data-bbox="779 1365 1063 1407">Number</th> <th data-bbox="1063 1365 1334 1407">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="779 1407 1063 1449">90,331,072</td> <td data-bbox="1063 1407 1334 1449">Ordinary shares</td> </tr> <tr> <td data-bbox="779 1449 1063 1491">16,284,981</td> <td data-bbox="1063 1449 1334 1491">Options</td> </tr> </tbody> </table>		Number	+Class	90,331,072	Ordinary shares	16,284,981	Options
Number	+Class							
90,331,072	Ordinary shares							
16,284,981	Options							

+ See chapter 19 for defined terms.

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)	2,750,000	Options expiring 17/08/12 exercise at \$0.20
	1,500,000	Options expiring 17/08/12 exercise at \$0.20
	2,500,000	Options expiring 17/08/12 exercise at \$0.20
	850,000	Options expiring 17/01/11 exercise at \$0.20

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	No change to dividend policy. Should dividends become payable in the future, available to participate from date of issue.
---	---

Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required?	N/A
12 Is the issue renounceable or non-renounceable?	N/A
13 Ratio in which the +securities will be offered	N/A
14 +Class of +securities to which the offer relates	N/A
15 +Record date to determine entitlements	N/A
16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17 Policy for deciding entitlements in relation to fractions	N/A

+ See chapter 19 for defined terms.

18	Names of countries in which the entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do +security holders sell their entitlements <i>in full</i> through a broker?	N/A

+ See chapter 19 for defined terms.

- | | | |
|----|--|-----|
| 31 | How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance? | N/A |
| 32 | How do +security holders dispose of their entitlements (except by sale through a broker)? | N/A |
| 33 | +Despatch date | N/A |

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities
(tick one)
- (a) Securities described in Part 1
- (b) All other securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
 WILL BE PROVIDED ON DESPATCH DATE
- 36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
 1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
WILL BE PROVIDED ON DESPATCH DATE

+ See chapter 19 for defined terms.

37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)	<input type="text"/>	<input type="text"/>

+ See chapter 19 for defined terms.

Quotation agreement

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

+ See chapter 19 for defined terms.



Sign here:
Company Secretary

Date: 30 August, 2010

Print name: Peter M Emery

=====

+ See chapter 19 for defined terms.